JP2023530092A - 精神障害又は精神高揚に有利なベンゾフラン組成物 - Google Patents

精神障害又は精神高揚に有利なベンゾフラン組成物 Download PDF

Info

Publication number
JP2023530092A
JP2023530092A JP2022576058A JP2022576058A JP2023530092A JP 2023530092 A JP2023530092 A JP 2023530092A JP 2022576058 A JP2022576058 A JP 2022576058A JP 2022576058 A JP2022576058 A JP 2022576058A JP 2023530092 A JP2023530092 A JP 2023530092A
Authority
JP
Japan
Prior art keywords
formula
compound
pharmaceutically acceptable
enantiomerically enriched
enantiomer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022576058A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023530092A5 (https=
Inventor
マシュー バゴット
Original Assignee
タクトジェン インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by タクトジェン インコーポレイテッド filed Critical タクトジェン インコーポレイテッド
Publication of JP2023530092A publication Critical patent/JP2023530092A/ja
Publication of JP2023530092A5 publication Critical patent/JP2023530092A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/78—Benzo [b] furans; Hydrogenated benzo [b] furans
    • C07D307/79—Benzo [b] furans; Hydrogenated benzo [b] furans with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
    • C07D307/81—Radicals substituted by nitrogen atoms not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/78—Benzo [b] furans; Hydrogenated benzo [b] furans
    • C07D307/79—Benzo [b] furans; Hydrogenated benzo [b] furans with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/78—Benzo [b] furans; Hydrogenated benzo [b] furans
    • C07D307/79—Benzo [b] furans; Hydrogenated benzo [b] furans with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
    • C07D307/80—Radicals substituted by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D317/00—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D317/08—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
    • C07D317/44—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D317/46—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • C07D317/48—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring
    • C07D317/50—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to atoms of the carbocyclic ring
    • C07D317/58—Radicals substituted by nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/07—Optical isomers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Emergency Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Addiction (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Furan Compounds (AREA)
  • Medicinal Preparation (AREA)
JP2022576058A 2020-06-08 2021-06-08 精神障害又は精神高揚に有利なベンゾフラン組成物 Pending JP2023530092A (ja)

Applications Claiming Priority (15)

Application Number Priority Date Filing Date Title
US202063036382P 2020-06-08 2020-06-08
US63/036,382 2020-06-08
US202063046496P 2020-06-30 2020-06-30
US63/046,496 2020-06-30
US202063048616P 2020-07-06 2020-07-06
US63/048,616 2020-07-06
US202063055897P 2020-07-23 2020-07-23
US63/055,897 2020-07-23
US202063062434P 2020-08-06 2020-08-06
US63/062,434 2020-08-06
US202163149223P 2021-02-13 2021-02-13
US63/149,223 2021-02-13
US202163165731P 2021-03-24 2021-03-24
US63/165,731 2021-03-24
PCT/US2021/036479 WO2021252538A2 (en) 2020-06-08 2021-06-08 Advantageous benzofuran compositions for mental disorders or enhancement

Publications (2)

Publication Number Publication Date
JP2023530092A true JP2023530092A (ja) 2023-07-13
JP2023530092A5 JP2023530092A5 (https=) 2024-06-12

Family

ID=78845853

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022576058A Pending JP2023530092A (ja) 2020-06-08 2021-06-08 精神障害又は精神高揚に有利なベンゾフラン組成物

Country Status (10)

Country Link
US (4) US11767305B2 (https=)
EP (1) EP4161503A4 (https=)
JP (1) JP2023530092A (https=)
KR (1) KR20230066313A (https=)
CN (2) CN116075300B (https=)
AU (1) AU2021289434A1 (https=)
CA (1) CA3179785A1 (https=)
IL (1) IL298769A (https=)
MX (1) MX2022015613A (https=)
WO (1) WO2021252538A2 (https=)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3519816A4 (en) 2016-09-29 2020-05-06 The Regents of the University of California CONNECTIONS FOR INCREASING NEURONAL PLASTICITY
WO2020157972A1 (en) * 2019-02-01 2020-08-06 Nec Corporation Estimation apparatus, method and program
KR102946120B1 (ko) 2019-02-27 2026-03-30 더 리젠츠 오브 더 유니버시티 오브 캘리포니아 뇌 장애를 치료하기 위한 아제피노-인돌 및 다른 헤테로사이클
CN116075300B (zh) * 2020-06-08 2025-08-05 泰科根公司 用于精神障碍或精神增强的有利苯并呋喃组合物
CN116209657A (zh) 2020-08-06 2023-06-02 泰科根公司 用于精神障碍或增强的2-氨基茚满化合物
CN116634912A (zh) * 2020-12-23 2023-08-22 新埃莫斯欧洲有限责任公司 电动抽吸头
WO2022251699A1 (en) * 2021-05-28 2022-12-01 Adamo Bioscience Inc. Compositions and methods for treatment of sexual dysfunction and related diseases, disorders, and conditions
AU2022283967A1 (en) 2021-06-03 2024-01-18 Arcadia Medicine, Inc. Enantiomeric entactogen compositions and methods of their use
EP4370114A4 (en) * 2021-07-14 2025-12-24 Mydecine Innovations Group Inc NEW SHORT-ACTING PSYCHOACTIVE COMPOUNDS OF THE MDMA CLASS
US12492178B2 (en) 2021-09-01 2025-12-09 Empathbio, Inc. Stable polymorph of R-MDMA HCl
EP4396305B1 (en) 2021-09-01 2026-05-06 EmpathBio, Inc. Synthesis of mdma or its optically active (r)- or (s)-mdma isomers
WO2023056102A1 (en) 2021-10-01 2023-04-06 ATAI Life Sciences AG Novel prodrugs of mdma, mda, and derivatives thereof
WO2023107653A2 (en) * 2021-12-08 2023-06-15 Tactogen Inc Benzofuran salt morphic forms and mixtures for the treatment of mental disorders or mental enhancement
CA3239514A1 (en) * 2021-12-09 2023-06-15 Matthew J. Baggott Specialized combinations for mental disorders or mental enhancement
IL313455A (en) 2021-12-15 2024-08-01 Delix Therapeutics Inc Phenoxy and benzyloxy modified psychroplastogens and their uses
US11912680B2 (en) 2021-12-28 2024-02-27 Empathbio, Inc. Nitric oxide releasing prodrugs of MDA and MDMA
WO2023168023A1 (en) 2022-03-04 2023-09-07 Reset Pharmaceuticals, Inc. Co-crystals or salts comprising psilocin
WO2024206712A1 (en) * 2023-03-31 2024-10-03 Tactogen Inc. Advantageous fluorobenzofurans for the treatment of mental disorders or enhancement
EP4727538A2 (en) * 2023-06-15 2026-04-22 Tactogen Inc. New formulations for mental disorders or mental enhancement
WO2025137342A2 (en) * 2023-12-19 2025-06-26 2A Biosciences, Inc. 5-carboxamido and 5-carboxyalkyl phenethylamines
TW202602861A (zh) * 2024-03-08 2026-01-16 新加坡商歐托梅拉公司 用於靶向自噬之苯并呋喃衍生物
WO2025217471A1 (en) * 2024-04-10 2025-10-16 2A Biosciences, Inc. 2-hemifly phenethylamines
CN120865133A (zh) * 2024-04-30 2025-10-31 山东全重生物医药科技有限公司 一类单胺递质再摄取抑制剂化合物及其制备方法和应用

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007500718A (ja) * 2003-07-30 2007-01-18 ワイス ３−アミノクロマンおよび２−アミノテトラリン誘導体
US20090048288A1 (en) * 2007-08-13 2009-02-19 H. Lundbeck A/S Method of treating stress-mediated depression

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR9406823A (pt) 1993-06-14 1996-03-26 Pfizer Aminas secundárias e agentes anti-diabéticos e antiobesidade
JP2000511518A (ja) 1996-05-14 2000-09-05 グラクソ、グループ、リミテッド 時間生物学的薬剤としてのベンゾフランおよびベンゾピラン
US7045545B1 (en) 1999-01-27 2006-05-16 Eli Lilly And Company Aminoalkylbenzofurans as serotonin (5-HT(2c)) agonists
JP2002535396A (ja) 1999-01-27 2002-10-22 イーライ・リリー・アンド・カンパニー セロトニン（５−ｈｔ（２ｃ））アゴニストとしてのアミノアルキルベンゾフラン類
US7218867B2 (en) 2004-08-27 2007-05-15 Static Control Components, Inc. Systems and methods for imaging components
CA2604915A1 (en) 2005-04-22 2006-11-02 Wyeth New therapeutic combinations for the treatment or prevention of depression
US7368477B2 (en) 2005-04-22 2008-05-06 Wyeth Benzofuranyl alkanamine derivatives and uses thereof
CA2605580A1 (en) * 2005-04-22 2006-11-02 Wyeth Benzodioxane and benzodioxolane derivatives and uses thereof
WO2007146890A2 (en) * 2006-06-09 2007-12-21 Auspex Pharmaceuticals, Inc. Preparation and utility of substituted pyrazole compounds with cannabinoid receptor activity
CN107406369B (zh) 2014-12-09 2021-01-15 以西结·戈兰 放纵行为调节剂
US11045454B2 (en) 2018-12-06 2021-06-29 Palo Alto Investors LP Methods of treating food allergy conditions
JP2023515616A (ja) 2020-02-28 2023-04-13 ユニヴェルシテートスピタル バーゼル ５ｈｔ２ａアゴニストの投与後の抑制効果
WO2021225796A1 (en) 2020-05-05 2021-11-11 Universitätsspital Basel Mdma treatment to enhance acute emotional effects profile of lsd, psilocybin or other psychedelics
CN116075300B (zh) 2020-06-08 2025-08-05 泰科根公司 用于精神障碍或精神增强的有利苯并呋喃组合物
BR112022025317A2 (pt) 2020-06-15 2023-01-03 Univ Basel Método de dosagem de um empatógeno/entactógeno no tratamento de pacientes; método para determinar uma dose de um empatógeno/entactógeno com base no peso corporal, sexo e atividade de cyp2d6; método para refinar a dosagem de um empatógeno/entactógeno; método para predizer a dosagem futura com um empatógeno/entactógeno; método para avaliar a viabilidade de pacientes para receber um empatógeno/entactógeno como tratamento; e método para otimizar o tratamento com empatógeno/entactógeno em um paciente
TW202216676A (zh) 2020-07-06 2022-05-01 美商塔朵根公司 用於心理疾病或心理強化的有益苯并噻吩組合物
EP4192451A4 (en) 2020-08-05 2024-08-14 Universitätsspital Basel METHOD OF ADMINISTERING INTRAVENOUS DMT FOR DMT-ASSISTED PSYCHOTHERAPY
CN116209657A (zh) 2020-08-06 2023-06-02 泰科根公司 用于精神障碍或增强的2-氨基茚满化合物
AU2021343525A1 (en) 2020-09-20 2023-05-18 Tactogen Inc Advantageous tryptamine compositions for mental disorders or enhancement
CA3199184A1 (en) 2020-11-18 2022-05-27 Felix Lustenberger Mdma prodrugs to assist psychotherapy
WO2022109050A1 (en) 2020-11-18 2022-05-27 Bexson Biomedical, Inc. Complexing agent salt formulations of pharmaceutical compounds
CA3203642A1 (en) 2020-12-02 2022-06-09 The Johns Hopkins University Restoration of motor function post-neurological injury using psychedelics
AU2022382937A1 (en) 2021-11-03 2024-05-16 Tactogen Inc Indolizine compounds for the treatment of mental disorders or mental enhancement
WO2023107653A2 (en) 2021-12-08 2023-06-15 Tactogen Inc Benzofuran salt morphic forms and mixtures for the treatment of mental disorders or mental enhancement
CA3239514A1 (en) 2021-12-09 2023-06-15 Matthew J. Baggott Specialized combinations for mental disorders or mental enhancement
NL2031332B1 (en) 2022-03-18 2023-09-29 Plethora Therapeutics B V Transmucosal delivery of psychoactive compounds
WO2023183613A2 (en) 2022-03-24 2023-09-28 Tactogen Inc Indolizine compounds for the treatment of mental disorders or inflammation

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007500718A (ja) * 2003-07-30 2007-01-18 ワイス ３−アミノクロマンおよび２−アミノテトラリン誘導体
US20090048288A1 (en) * 2007-08-13 2009-02-19 H. Lundbeck A/S Method of treating stress-mediated depression

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
ESHLEMAN, AMY J. ET AL.: ""Structure-activity relationships of bath salt components: substituted cathinones and benzofurans a", PSYCHOPHARMACOLOGY, vol. 236, no. 3, JPN6025016197, 2018, pages 939 - 952, ISSN: 0005577629 *
JOYCE, B. MATTHEW ET AL.: ""Adderall produces increased striatal dopamine release and a prolonged time course compared to amph", PSYCHOPHARMACOLOGY, vol. 191, no. 3, JPN6025016198, 2006, pages 669 - 677, ISSN: 0005765197 *
KIAN KADKHODAEI; ET AL: "SEPARATION OF ENANTIOMERS OF NEW PSYCHOACTIVE SUBSTANCES BY HIGH-PERFORMANCE LIQUID CHROMATOGRAPHY", JOURNAL OF SEPARATION SCIENCE, vol. VOL:41, NR:6, JPN5024000371, March 2018 (2018-03-01), pages 1274 - 1286, ISSN: 0005765195 *
SHIMSHONI, JAKOB A. ET AL.: ""Neurochemical binding profiles of novel indole and benzofuran MDMA analogues"", NAUNYN-SCHMIEDEBERG'S ARCHIVES OF PHARMACOLOGY, vol. 390, no. 1, JPN6025016199, 2016, pages 15 - 24, ISSN: 0005765196 *

Also Published As

Publication number Publication date
IL298769A (en) 2023-02-01
EP4161503A2 (en) 2023-04-12
US20230150963A1 (en) 2023-05-18
US12365661B2 (en) 2025-07-22
US20240083864A1 (en) 2024-03-14
EP4161503A4 (en) 2024-07-03
CN116075300B (zh) 2025-08-05
CN116075300A (zh) 2023-05-05
CA3179785A1 (en) 2021-12-16
KR20230066313A (ko) 2023-05-15
WO2021252538A2 (en) 2021-12-16
AU2021289434A1 (en) 2023-01-19
US12344591B2 (en) 2025-07-01
US20250188049A1 (en) 2025-06-12
MX2022015613A (es) 2023-04-04
US20250034102A1 (en) 2025-01-30
US12404257B2 (en) 2025-09-02
CN120040398A (zh) 2025-05-27
US11767305B2 (en) 2023-09-26
WO2021252538A3 (en) 2022-01-20

Similar Documents

Publication Publication Date Title
US12404257B2 (en) Advantageous benzofuran compositions for mental disorders or enhancement
US12459912B2 (en) Advantageous benzothiophene compositions for mental disorders or enhancement
WO2022061242A1 (en) Advantageous tryptamine compositions for mental disorders or enhancement
US12454515B2 (en) 2-aminoindane compounds for mental disorders or enhancement
AU2022382937A1 (en) Indolizine compounds for the treatment of mental disorders or mental enhancement
US20250019357A1 (en) Benzofuran salt morphic forms and mixtures for the treatment of mental disorders or mental enhancement
TW202216674A (zh) 用於心理疾病或心理強化的有益苯并呋喃組合物
EA052423B1 (ru) Перспективные бензофурановые композиции для лечения психических расстройств или улучшения психического состояния
WO2024108179A2 (en) 2-ethylamine substituted benzofuran and benzothiophene compositions for mental disorders or enhancement
WO2024206712A1 (en) Advantageous fluorobenzofurans for the treatment of mental disorders or enhancement

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240604

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20240604

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250422

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20250424

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20250718

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20250909

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20251021

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20260106